TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38307722

Group type: EXPERIMENTAL
Intervention: MMA embolization within 7 days of burr-hole surgery
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 342
Study: 38307927

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 4930
Study: 38307966

Group type: EXPERIMENTAL
Intervention: Immunization with Plasmodium vivax radiation-attenuated sporozoites (PvRAS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mock vaccination
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Immunization with non-irradiated Pv-infected mosquitoes (live sporozoites)
Number of subjects: 12
Study: 38308203

Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: T2DM patients after drug-induced mydriasis
Number of subjects: 84

Group type: COMPARATOR
Intervention: T1DM patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 84
Study: 38308227

Group type: EXPERIMENTAL
Intervention: Fish oil capsules containing n-3 LCPUFAs
Number of subjects: 120

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 120
Study: 38308248

Group type: EXPERIMENTAL
Intervention: Aquatic exercise intervention group (8-week, twice-weekly group-based Ai-Chi program)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: On-land exercise group (identical exercise to aquatic group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 150
Study: 38308310

Group type: EXPERIMENTAL
Intervention: Phase angle (PhA) cut-off point of 3.73°
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Reduced exercise tolerance defined as performance ≤50% of the predicted value in the six-minute step test (6MST)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inflammatory and nutritional status, body composition, peripheral muscle strength
Number of subjects: 31
Study: 38308331

Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Number of subjects: 23

Group type: COMPARATOR
Intervention: CDC-recommended funding
Number of subjects: 23

Group type: COMPARATOR
Intervention: American Lung Association smoke-free scores
Number of subjects: 23
Study: 38308336

Group type: EXPERIMENTAL
Intervention: K Nearest Neighbors algorithm
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Machine learning models (various)
Number of subjects: 162
Study: 38308377

Group type: EXPERIMENTAL
Intervention: Online nurse-assisted eye screening
Number of subjects: 240

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 240
Study: 38308453

Group type: EXPERIMENTAL
Intervention: MMR vaccine (with or without varicella vaccine); 5 children with a ≤12-week gap (1-7 weeks) between dupilumab administration and vaccination.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MMR vaccine (with or without varicella vaccine); 4 children with a >12-week gap after discontinuing dupilumab.
Number of subjects: 9
Study: 38308655

Group type: EXPERIMENTAL
Intervention: Izuforant 100 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 38308727

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 629
Study: 38308746

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) combined with photodynamic therapy (PDT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) alone (monotherapy)
Number of subjects: 90
Study: 38308771

Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6
Number of subjects: 155

Group type: COMPARATOR
Intervention: placebo-mFOLFOX6
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6 (in FGFR2b-positive GC in ≥10% of tumor cells)
Number of subjects: 155
Study: 38309033

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (INT)
Number of subjects: 1847

Group type: COMPARATOR
Intervention: Minimalist follow-up (MIN)
Number of subjects: 1847
Study: 38309227

Group type: EXPERIMENTAL
Intervention: 100 mg 5-HTP daily
Number of subjects: 30
Study: 38309228

Group type: EXPERIMENTAL
Intervention: Low arginine levels ≤90.05 μmol/l (n = 86; 37%)
Number of subjects: 231
Study: 38309282

Group type: EXPERIMENTAL
Intervention: Tabelecleucel administered intravenously at 2 × 10^6 cells/kg
Number of subjects: 43
Study: 38309287

Group type: EXPERIMENTAL
Intervention: Penpulimab plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Number of subjects: 350
Study: 38309492

Group type: EXPERIMENTAL
Intervention: H-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 10 days)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: H-VA-14 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 14 days)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days)
Number of subjects: 516
Study: 38309519

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir for 6 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 38309610

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI followed by TAVI
Number of subjects: 328

Group type: COMPARATOR
Intervention: CABG and SAVR
Number of subjects: 328
Study: 38309696

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38309721

Group type: EXPERIMENTAL
Intervention: TIL therapy with lymphodepleting chemotherapy followed by infusion of ex vivo expanded TIL manufactured with IL-2 and agonistic stimulation of CD3 and 4-1BB (urelumab); patients received up to six doses of high-dose IL-2 after TIL infusion.
Number of subjects: 16
Study: 38309722

Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (cervical cancer; n=15)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-CRC; n=15)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (NSCLC; n=20)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (ovarian cancer; n=40)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-endometrial cancer; n=40)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Monalizumab plus durvalumab
Number of subjects: 185
Study: 38309733

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 4.5; mean ideal cuff volume inflated was 1.7±0.3 ml
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 5.0; mean ideal cuff volume inflated was 1.9±0.3 ml
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 5.5; mean ideal cuff volume inflated was 2.1±0.3 ml
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Formula developed for predicting cuff volume: endotracheal cuff volume (ml) = 1.027 x height (m) + 0.104 x subglottic transverse diameter (mm) - 0.0191
Number of subjects: 127
Study: 38309748

Group type: EXPERIMENTAL
Intervention: SCRT followed by four cycles of CAPOX and PD-1 inhibitor (serplulimab)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Four cycles of capecitabine plus oxaliplatin (CAPOX)
Number of subjects: 120
Study: 38309755

Group type: EXPERIMENTAL
Intervention: BioMEL biobank
Number of subjects: 0
Study: 38309757

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 1204

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1204
Study: 38309759

Group type: EXPERIMENTAL
Intervention: Adaptive, multifaceted intervention in general practice, including extended consultations based on a patient-centred framework.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group continuing care as usual.
Number of subjects: 250
Study: 38309761

Group type: EXPERIMENTAL
Intervention: CSA-coated ETT (CeraShield N8 Pharma)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ETT with subglottic secretion drainage (Taper Guard, Covidien)
Number of subjects: 0
Study: 38309828

Group type: EXPERIMENTAL
Intervention: High temperatures (measured as maximum air temperature)
Number of subjects: 5039
Study: 38309829

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) during pregnancy and 6 months postpartum
Number of subjects: 966

Group type: COMPARATOR
Intervention: Control group (iron and folic acid (IFA) during pregnancy and placebo postpartum or multiple micronutrients (MMNs) during pregnancy and postpartum)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 966
Study: 38309831

Group type: EXPERIMENTAL
Intervention: COVID-19 infection (Cohort-1)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Milk bank donors (Cohort-2)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Vaccination (Cohort-3)
Number of subjects: 488
Study: 38310035

Group type: EXPERIMENTAL
Intervention: Domvanalimab 1200 mg plus zimberelimab 360 mg plus platinum-doublet chemotherapy (PT)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg plus PT
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Zimberelimab 360 mg plus PT
Number of subjects: 720
Study: 38310163

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 636

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 636
Study: 38310192

Group type: EXPERIMENTAL
Intervention: KN046 (3 mg/kg or 5 mg/kg) combined with nab-paclitaxel
Number of subjects: 27
Study: 38310232

Group type: EXPERIMENTAL
Intervention: YRI + mobile supervision
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: YRI + standard supervision
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1200
Study: 38310236

Group type: COMPARATOR
Intervention: Brush/Rinse (EO alcohol-containing mouthrinse)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Brush/Rinse (EO non-alcohol containing mouthrinse)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Brush/Floss/Rinse (EO non-alcohol containing mouthrinse)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Brush/Floss
Number of subjects: 270
Study: 38310249

Group type: EXPERIMENTAL
Intervention: External beam accelerated partial breast irradiation (APBI)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Moderate hypofractionated whole breast irradiation (WBI)
Number of subjects: 84
Study: 38310261

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at week 0, week 4, then every 8 weeks
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab (pooled N=493)
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 739

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739
Study: 38310262

Group type: EXPERIMENTAL
Intervention: Single fraction stereotactic ablative radiotherapy (SF SABR)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Multiple fraction stereotactic ablative radiotherapy (MF SABR)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: Radiation-related symptom questionnaire-guided healthcare provider intervention
Number of subjects: 598

Group type: COMPARATOR
Intervention: Quality of life questionnaires only
Number of subjects: 598
Study: 38310268

Group type: EXPERIMENTAL
Intervention: EPIC Urinary Irritative/Obstructive subscale
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: EPIC Urinary Summary
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Linear regressions
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Complex model architectures
Number of subjects: 347
Study: 38310274

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery (Mazor X Stealth Edition)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Freehand surgery with 2D fluoroscopy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 300
Study: 38310286

Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m²) and Anlotinib
Number of subjects: 8
Study: 38310565

Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg or ~6 mg/kg induction dose followed by 90 mg subcutaneous maintenance doses q8w or q12w)
Number of subjects: 2575

Group type: COMPARATOR
Intervention: Placebo (single intravenous dose followed by subcutaneous maintenance doses)
Number of subjects: 2575
Study: 38310863

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 702
Study: 38310875

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 38310910

Group type: EXPERIMENTAL
Intervention: R21/Matrix-M vaccine
Number of subjects: 5477

Group type: COMPARATOR
Intervention: Control vaccine (licensed rabies vaccine [Abhayrab])
Number of subjects: 5477
Study: 38310920

Group type: EXPERIMENTAL
Intervention: NNC0385-0434 15 mg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: NNC0385-0434 40 mg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: NNC0385-0434 100 mg
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 38310918

Group type: EXPERIMENTAL
Intervention: Hydrocortisone plus fludrocortisone
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study: 38311016

Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF) applied once at baseline
Number of subjects: 360

Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF) applied at baseline and after 6 months
Number of subjects: 360
Study: 38311065

Group type: EXPERIMENTAL
Intervention: Faba bean protein
Number of subjects: 9
Study: 38311111

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin plus bendamustine and rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brentuximab vedotin (as a comparison)
Number of subjects: 0
Study: 38311207

Group type: EXPERIMENTAL
Intervention: GA location as assessed by the ETDRS grid
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Low-luminance visual acuity (LLVA)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Reading acuity and speed
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: GA area
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VRQoL scores associated with different GA subfields
Number of subjects: 82
Study: 38311797

Group type: COMPARATOR
Intervention: Nomlabofusp (25, 50, 75, or 100 mg single doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nomlabofusp (25 mg daily for 4 days then every third day, 50 mg daily for 7 days then every 2 days, or 100 mg daily for 13 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nomlabofusp (various dosing regimens)
Number of subjects: 55
Study: 38311806

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg once daily
Number of subjects: 82
Study: 38312029

Group type: EXPERIMENTAL
Intervention: Standardized trauma intake form (TIF)
Number of subjects: 4077
Study: 38312102

Group type: EXPERIMENTAL
Intervention: Guadecitabine and irinotecan (Arm A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard of care (regorafenib or TAS-102) (Arm B)
Number of subjects: 104
Study: 38312142

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (four individual counseling sessions with a registered dietitian, 10 informative video clips, and a virtual support community)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual prenatal care
Number of subjects: 150
Study: 38312212

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 38312234

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control
Number of subjects: 210
Study: 38312318

Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy (HDRBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose-rate brachytherapy (LDRBT)
Number of subjects: 0
Study: 38312435

Group type: EXPERIMENTAL
Intervention: Halova vaginal ovules
Number of subjects: 0
Study: 38312459

Group type: EXPERIMENTAL
Intervention: F/TAF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F/TDF
Number of subjects: 0
Study: 38312795

Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 38312972

Group type: EXPERIMENTAL
Intervention: Sagittal Split Plate (SSOP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Two Miniplates
Number of subjects: 38
Study: 38313142

Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (CBT) combining an Internet-based program with videoconference sessions every 10-12 days, containing seven modules.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Blended cognitive-behavioral intervention (CBT)
Number of subjects: 41
Study: 38313251

Group type: EXPERIMENTAL
Intervention: Higher SM Group (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower SM Group (n = 10)
Number of subjects: 20
Study: 38313271

Group type: EXPERIMENTAL
Intervention: Ultra-low-field portable MRI (ULF-pMRI)
Number of subjects: 50
Study: 38313407

Group type: EXPERIMENTAL
Intervention: Cognitive-coupled intensive balance training (CIBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 32
Study: 38313767

Group type: EXPERIMENTAL
Intervention: Intravenous mirikizumab 300 mg every 4 weeks for 12 weeks (LUCENT-1)
Number of subjects: 1706

Group type: EXPERIMENTAL
Intervention: Subcutaneous mirikizumab 200 mg every 4 weeks through Week 40 (LUCENT-2)
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 12 weeks (LUCENT-1)
Number of subjects: 1706

Group type: COMPARATOR
Intervention: Placebo every 4 weeks through Week 40 (LUCENT-2)
Number of subjects: 1706
Study: 38314010

Group type: EXPERIMENTAL
Intervention: TheraTogs + Conventional Physical Therapy (CPT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional Physical Therapy (CPT)
Number of subjects: 34
Study: 38314063

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38314087

Group type: EXPERIMENTAL
Intervention: Chimeric CD70-Peptide Vaccine
Number of subjects: 0
Study: 38314118

Group type: EXPERIMENTAL
Intervention: Night-time sleep duration at 6 months postpartum
Number of subjects: 0
Study: 38314243

Group type: EXPERIMENTAL
Intervention: vWF concentrates
Number of subjects: 497

Group type: COMPARATOR
Intervention: Platelet concentrates
Number of subjects: 497
Study: 38314254

Group type: EXPERIMENTAL
Intervention: Family-Scouts intervention (a fixed contact person who advises, accompanies, and supports the families)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family-Scouts intervention
Number of subjects: 0
Study: 38314536

Group type: EXPERIMENTAL
Intervention: Surgery with VR glasses
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgery without VR glasses (Control)
Number of subjects: 58
Study: 38314554

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 337
Study: 38314643

Group type: EXPERIMENTAL
Intervention: Buspirone/Zolmitriptan (10/1.25 mg three times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38314779

Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound to anterior insula (AI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-intensity focused ultrasound to posterior insula (PI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 23
Study: 38314943

Group type: EXPERIMENTAL
Intervention: Age-specific PANIC cutoffs
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: NHANES-based cutoffs
Number of subjects: 1044
Study: 38315156

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, bupivacaine, and epinephrine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Bupivacaine and epinephrine (control group)
Number of subjects: 117
Study: 38315229

Group type: EXPERIMENTAL
Intervention: Flexible hyaluronic acid (HA) filler, Restylane
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study: 38315466

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel
Number of subjects: 5204

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 5204
Study: 38315470

Group type: EXPERIMENTAL
Intervention: Alirocumab Q2W
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Alirocumab Q4W
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 153
Study: 38315488

Group type: EXPERIMENTAL
Intervention: Behavioral intervention focused on resilience
Number of subjects: 0
Study: 38315489

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study: 38315503

Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring System
Number of subjects: 0
Study: 38315506

Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38315700

Group type: EXPERIMENTAL
Intervention: Systematic TB screening in facility-based child-health entry points, decentralisation of TB diagnosis and management, improved sample collection with access to Xpert® MTB/RIF or MTB/RIF Ultra testing, implementation of contact investigation.
Number of subjects: 1991401
Study: 38315721

Group type: EXPERIMENTAL
Intervention: Telehealth use
Number of subjects: 575

Group type: COMPARATOR
Intervention: Living in more disadvantaged areas (based on SDI)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Driving time from home to clinic (more than an hour)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Continuity of MOUD (180 days retention)
Number of subjects: 575